TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A University of Surrey-led randomized controlled trial found that participants taking NOVOS Core for six months had better results on three vascular health measures than participants taking a placebo. The 61-person study measured biomarkers, not heart attacks, strokes or other clinical outcomes, and researchers say larger studies are needed.
A University of Surrey-led randomized controlled trial found that adults taking the multi-component supplement NOVOS Core for six months had improved results on measures of endothelial function, arterial stiffness and systolic blood pressure compared with a placebo group. The 61-person trial assessed cardiovascular biomarkers rather than clinical outcomes, so it does not show whether the supplement prevents heart attacks, strokes or other disease.
The study enrolled 61 participants: 33 were assigned to take the supplement once daily and 28 to take a placebo, also once daily. Researchers tracked several indicators of vascular health during the six-month study. They reported a favorable between-group difference in flow-mediated dilation, a measure of how blood vessels respond and regulate their tone.
Some changes appeared soon after dosing. The researchers observed improved flow-mediated dilation one hour after the first dose; the placebo group’s measurements remained largely unchanged. A difference in systolic blood pressure was also seen after one hour. At six months, the adjusted difference in systolic blood pressure between groups was 6.1 mmHg in favor of the supplement.
Pulse wave velocity, a measure of arterial stiffness, was lower in the supplement group at six months, with an adjusted between-group difference of 1.18 m/s. Blood tests showed no significant changes in cholesterol or other blood lipids, according to the report. The estimated 10-year cardiovascular risk also fell modestly, largely reflecting the blood-pressure difference; that estimate is not evidence that participants experienced fewer cardiovascular events.
What the Vascular Measures Show
The results suggest that a multi-ingredient nutritional supplement may affect several vascular biomarkers at once, an approach the researchers studied because aging involves interacting biological processes. Endothelial function, arterial stiffness and blood pressure capture different aspects of vascular health and are associated with cardiovascular risk.
The reported blood-pressure difference may draw attention because earlier large studies have linked a sustained 5 mmHg reduction in systolic pressure with an approximately 10% reduction in major cardiovascular events. That comparison comes from previous research, not from this trial. The study did not follow participants long enough or enroll enough people to establish whether its measured changes last or lead to fewer events. It also cannot establish that the supplement would have the same effects in a broader population.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Levoit Core 400S-P Smart Air Purifier for Large Rooms (Up to 1,718 sq ft)
Levoit Eleva 300X Air Purifier with Sealed HEPA Filtration
As an affiliate, we earn on qualifying purchases.
How the Six-Month Trial Was Designed
The study, titled Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial, was published in European Heart Journal Open. The formulation combines vitamins and minerals, amino acids and plant-derived bioactive ingredients. The report describes these components as selected for their relevance to biological processes associated with aging; the supplied study summary does not provide a full ingredient list or establish which components, if any, drove the observed changes.
Researchers tested the idea that addressing several aging-related processes simultaneously could influence cardiovascular biomarkers. They did not test a single ingredient against a control, so the trial cannot identify the contribution of individual components. Its findings are a proof of concept, rather than evidence that the product treats cardiovascular disease.
“We now need larger studies to understand the mechanisms involved and, importantly, whether these changes translate into longer-term health benefits.”
— Professor Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey
Clinical Benefits Remain Unproven
The trial does not establish whether the observed changes produce fewer heart attacks, strokes or deaths, or whether they persist after people stop taking the supplement. With 61 participants, it was small, and the available report does not provide enough detail here to assess how well results apply to people with different ages, health conditions or medication use.
It is also unclear which ingredients may have contributed to the changes, whether the effects would be replicated in larger studies, and what the long-term safety profile would be. The reported lipid results showed no significant changes, but that does not explain the mechanisms behind the vascular findings. The study should not be treated as a basis for starting, stopping or replacing prescribed care.
Larger Studies Are the Next Test
The researchers say larger studies are needed to examine the biological mechanisms and determine whether changes in vascular markers translate into longer-term health benefits. Future research would need to test whether the measured effects are sustained and assess clinical outcomes over a longer period. The study report does not specify a timeline or confirm that a follow-up trial has begun.
Key Questions
What did the trial find?
Compared with a placebo group, participants taking NOVOS Core for six months showed favorable changes in measures of endothelial function, arterial stiffness and systolic blood pressure.
Did the study show that the supplement prevents heart attacks or strokes?
No. The trial measured vascular biomarkers and was not designed to assess heart attacks, strokes or other clinical outcomes.
How many people took part?
The study included 61 participants: 33 received the supplement and 28 received a placebo.
Did cholesterol levels change?
The report said blood tests found no significant changes in cholesterol or other blood lipids during the study.
What research is needed next?
Researchers called for larger studies to clarify how the changes occurred and whether they lead to sustained improvements or meaningful long-term health outcomes.
Source: news-medical.net
